Navigation Links
Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
Date:7/9/2012

Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit. This provides a new avenue toward eliminating the need to keep some vaccines and antibiotics refrigerated, which could save billions of dollars every year and increase accessibility to third world populations.

Vaccines and antibiotics often need to be refrigerated to prevent alteration of their chemical structures; such alteration can result in less potent or ineffective medications. By immobilizing their bioactive molecules using silk protein matrices, researchers were able to protect and stabilize both live vaccines and antibiotics when stored at higher than recommended temperatures for periods far longer than recommended.

The research was led by grantees of NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB), David Kaplan, Ph.D., and Jeney Zhang, Ph.D. candidate, at Tufts University School of Engineering in Medford, Mass. The National Eye Institute and the National Institute of Dental and Craniofacial Research at NIH also contributed to this research. The researchers reported on their findings in the online issue of Proceedings of the National Academy of Sciences on July 9, 2012.

"This truly exciting development is the culmination of years of creative exploration and research focused on a major problem in the delivery of health care. Dr. Kaplan and his team have done a masterful job at both understanding the key properties of silk, and applying these insights to a global medical challenge," said NIBIB Director Roderic I. Pettigrew, Ph.D., M.D. "This is also a wonderful validation of the type of team science we see in our Biotechnology Resource and Development Centers and their ability to combine cutting edge science in a number of fields to a variety of health needs."

Pettig
'/>"/>

Contact: Kate Egan
NIBIBPress@mail.nih.gov
301-451-0161
NIH/National Institute of Biomedical Imaging & Bioengineering
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Overweight? Theres a vaccine for that
2. Sensitive test helps improve vaccine safety
3. Army study: DNA vaccine and duck eggs protect against hantavirus disease
4. AAPS National Biotechnology Conference to highlight innovative vaccines
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. SFU HIV/AIDS vaccine research gets financial boost
7. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
8. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
9. Queens scientists seek vaccine for Pseudomonas infection
10. Toward an alternative for antibiotics to fight bacterial infections?
11. The effect of treatment with antibiotics and vaccination against Q fever in sheep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... YORK, March 24, 2010 Early-stage human clinical trials showed ... effects in a type of diabetic eye disease, and may ... macular edema. Researchers at the Wilmer Eye Institute of ... multicenter human clinical trial treating diabetic macular edema with mecamylamine, ...
... endangered freshwater mussel species has been given a welcome boost ... cultivation project. Over 300 of the mussels, which are ... been released back into the wild at a range of ... development, the conservation scientists from Queen,s will be able to ...
... of overeating at the Last Supper? Two brothersan eating ... might make you think twice at your Easter dinner. ... of food depicted in 52 of the best-known paintings of ... foods by the sizes of the average disciple,s head, they ...
Cached Biology News:JDRF funded researchers test topical drug to treat diabetic macular edema 2JDRF funded researchers test topical drug to treat diabetic macular edema 3Queen's scientists boost endangered freshwater mussels population 2
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
(Date:7/28/2015)... SINGAPORE , July 28, 2015  Faced ... treatments that are palliative rather than symptomatic, the ... With few existing therapies capable of curing or ... providers are starting to look towards regenerative medicine ... represents a new paradigm in human health with ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity filament yarn ... years in the EU. For instance, it surpassed the EUR 106 million mark (in ... in 2010. Germany is a major producer, while Italy is a key consumer. ...
(Date:7/27/2015)... 2015 According to the new Market ... Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by ... , Asia-Pacific , Rest of the ... media market was valued at $247.7 million in 2014, which ... at a CAGR of 18.2% between 2014 and 2019. ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3
... ARAY ), a global leader in the field ... officer, Euan S.,Thomson, Ph.D., is scheduled to present at ... in New York City, on Thursday, May,22, 2008 at ... webcast of the presentation will be available online from ...
... - IND for liquid formulation, NGX-1998, expected to be opened and, ... dermal patch, NGX-4010, in PHN expected in second half ... ... peripheral neuropathic pain, SAN MATEO, Calif., May 15 NeurogesX, Inc.,(Nasdaq: ...
... The REACH Registry reveals that 70% of deaths in the ... cardiovascular event other than stroke, NICE, France, May 15 ... European Stroke Congress, highlight that among,those who die after a ... events. The overall death rate is 4.45%, with,3.23% of these ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at CitiGroup Healthcare Conference 2NeurogesX Reports First Quarter 2008 Results 2NeurogesX Reports First Quarter 2008 Results 3NeurogesX Reports First Quarter 2008 Results 4NeurogesX Reports First Quarter 2008 Results 5NeurogesX Reports First Quarter 2008 Results 6NeurogesX Reports First Quarter 2008 Results 7Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5